Immunotherapy moves to the early-stage setting in non-small cell lung cancer: emerging evidence and the role of biomarkers
Keywords:
Immunotherapy
Early-stage
Non-small cell lung cancer
Biomarkers
PD-1
Nivolumab
Pembrolizumab
Atezolizumab
Durvalumab
Note:
This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Citation:
Mielgo-Rubio, X. (Xabier); Calvo, V. (Virginia); Luna, J. (Javier); et al. "Immunotherapy moves to the early-stage setting in non-small cell lung cancer: emerging evidence and the role of biomarkers". Cancers. 12 (11), 2018, 3459
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.